Your browser doesn't support javascript.
loading
Real-world evidence of biologic treatments in psoriatic arthritis in Italy: results of the CHRONOS (EffeCtiveness of biologic treatments for psoriatic artHRitis in Italy: an ObservatioNal lOngitudinal Study of real-life clinical practice) observational longitudinal study.
Colombo, Delia; Frassi, Micol; Pagano Mariano, Giusy; Fusaro, Enrico; Lomater, Claudia; Del Medico, Patrizia; Iannone, Florenzo; Foti, Rosario; Limonta, Massimiliano; Marchesoni, Antonio; Raffeiner, Bernd; Viapiana, Ombretta; Grassi, Walter; Grembiale, Rosa Daniela; Guggino, Giuliana; Mazzone, Antonino; Tirri, Enrico; Perricone, Roberto; Sarzi Puttini, Pier Carlo; De Vita, Salvatore; Conti, Fabrizio; Ori, Alessandra; Simoni, Lucia; Fiocchi, Martina; Orsenigo, Roberto; Zagni, Emanuela.
Afiliación
  • Colombo D; Novartis Farma S.p.A, Largo Umberto Boccioni, 1, 21040, Origgio, Varese, Italy.
  • Frassi M; ASST Spedali Civili, Brescia, Italy.
  • Pagano Mariano G; Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Reggio Calabria, Italy.
  • Fusaro E; AOU Città della Salute e della Scienza di Torino, Turin, Italy.
  • Lomater C; A.O. Mauriziano, Turin, Italy.
  • Del Medico P; Ospedale Civile, Civitanova Marche, Italy.
  • Iannone F; A.O.U. Policlinico Consorziale, Bari, Italy.
  • Foti R; A.O.U. Policlinico -Vittorio Emanuele, Catania, Italy.
  • Limonta M; ASST Papa Giovanni XXIII, Bergamo, Italy.
  • Marchesoni A; Department of Rheumatology, ASST Gaetano Pini-CTO, Milan, Italy.
  • Raffeiner B; Rheumatology, Humanitas San Pio X, Milan, Italy.
  • Viapiana O; Ospedale Centrale di Bolzano, Bolzano, Italy.
  • Grassi W; AOUI Verona Borgo Rome, Verona, Italy.
  • Grembiale RD; Policlinico A. Murri, Jesi, Italy.
  • Guggino G; A.O.U. Mater Domini, Catanzaro, Italy.
  • Mazzone A; A.O.U. Policlinico Giaccone, Palermo, Italy.
  • Tirri E; Ospedale Civile Di Legnano, Legnano, Italy.
  • Perricone R; Ospedale San Giovanni Bosco, Naples, Italy.
  • Sarzi Puttini PC; Policlinico Tor Vergata, Rome, Italy.
  • De Vita S; ASST FBF Sacco, Milan, Italy.
  • Conti F; ASUIUD, Udine, Italy.
  • Ori A; Azienda Policlinico Umberto I, Rome, Italy.
  • Simoni L; MediNeos Observational Research, Modena, Italy.
  • Fiocchi M; MediNeos Observational Research, Modena, Italy.
  • Orsenigo R; Novartis Farma S.p.A, Largo Umberto Boccioni, 1, 21040, Origgio, Varese, Italy.
  • Zagni E; Novartis Farma S.p.A, Largo Umberto Boccioni, 1, 21040, Origgio, Varese, Italy.
BMC Rheumatol ; 6(1): 57, 2022 Sep 12.
Article en En | MEDLINE | ID: mdl-36089612
BACKGROUND: Biologics have demonstrated efficacy in PsA in randomized clinical trials. More evidence is needed on their effectiveness under real clinical practice conditions. The aim of the present work is to provide real-world evidence of the effectiveness of biologics for PsA in the daily clinical practice. METHODS: CHRONOS was a multicenter, non-interventional, cohort study conducted in 20 Italian hospital rheumatology clinics. RESULTS: 399 patients were eligible (56.9% females, mean (SD) age: 52.4 (11.6) years). The mean (SD) duration of PsA and psoriasis was 7.2 (6.9) and 15.3 (12.2) years, respectively. The mean (SD) duration of the biologic treatment under analysis was 18.6 (6.5) months. The most frequently prescribed biologic was secukinumab (40.4%), followed by adalimumab (17.8%) and etanercept (16.5%). The proportion of overall responders according to EULAR DAS28 criteria was 71.8% (95% CI: 66.7-76.8%) out of 308 patients at 6 months and 68.0% (95% CI: 62.7-73.3%) out of 297 patients at 1 year. Overall, ACR20/50/70 responses at 6 months were 41.2% (80/194), 29.4% (57/194), 17.1% (34/199) and at 1-year were 34.9% (66/189), 26.7% (51/191), 18.4% (36/196), respectively. Secondary outcome measures improved rapidly already at 6 months: mean (SD) PASI, available for 87 patients, decreased from 3.2 (5.1) to 0.6 (1.3), the proportion of patients with dactylitis from 23.6% (35/148) to 3.5% (5/142) and those with enthesitis from 33.3% (49/147) to 9.0% (12/133). CONCLUSIONS: The CHRONOS study provides real-world evidence of the effectiveness of biologics in PsA in the Italian rheumatological practice, confirming the efficacy reported in RCTs across various outcome measures.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Evaluation_studies / Observational_studies Idioma: En Revista: BMC Rheumatol Año: 2022 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Evaluation_studies / Observational_studies Idioma: En Revista: BMC Rheumatol Año: 2022 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido